Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04204616 · ClinicalTrials.gov registry record · Phase 3
A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
A Phase 3 study of Prurigo Nodularis, sponsored by Galderma R&D.
- Active
- Registry status
- Phase 3
- Development phase
- 500
- Enrollment target
- 20
- Study locations
NCT04204616 is a Phase 3 study of Prurigo Nodularis that is active but no longer recruiting, run by Galderma R&D. The registered enrollment target is 500 participants, above the 194-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (158% higher). The trial reports 20 study locations across 5 states.
The verdict
NCT04204616, a Phase 3 study of Prurigo Nodularis, is active but no longer recruiting, sponsored by Galderma R&D.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 500 participants
- Enrollment target
- 20
- Study locations
Study Summary
The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
Conditions Studied
Interventions
- DRUG Nemolizumab
Study Locations (20)
Florida
- Galderma Investigational Site - Aventura
- Galderma Investigational Site - Delray Beach
- Galderma Investigational Site - Hollywood
- Galderma Investigational Site - Largo
- Galderma Investigational Site - Miami
- Galderma Investigational Site - Miami
- Galderma Investigational Site - North Miami Beach
- Galderma Investigational Site - Ormond Beach
- Galderma Investigational Site - Pembroke Pines
- Galderma Investigational Site - Tampa
California
- Galderma Investigational Site - Fountain Valley
- Galderma Investigational Site - Los Angeles
- Galderma Investigational Site - San Diego
- Galderma Investigational Site - San Diego
- Galderma Investigational Site - Santa Monica
Alabama
- Galderma Investigational Site - Birmingham
- Galderma Investigational Site - Birmingham
Georgia
- Galderma Investigational Galderma Investigational Site - Columbus
- Galderma Investigational Site - Macon
District of Columbia
- Galderma Investigational Site - Washington D.C.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 500 participants |
| Start Date | 2021-01-11 |
| Est. Completion | 2026-10-26 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04204616
The ClinicalTrials.gov registry entry for NCT04204616 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 500 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 194-participant average among 14 other Prurigo Nodularis trials with a reported enrollment target (158% higher). The listed sponsor is Galderma R&D, which has 158 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Prurigo Nodularis appearing as the primary indexed condition, and to 1 intervention - of which Nemolizumab is the first listed.
NCT04204616 reports 20 study locations spanning 5 distinct geographic areas - top geographies include Florida, California, Alabama.
Frequently Asked Questions
What is clinical trial NCT04204616 about?
NCT04204616 is a clinical study titled "A Long-term Study of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)". The primary purpose of this study is to assess the long-term safety of nemolizumab (CD14152) in participants with prurigo nodularis (PN).
What is the current status of trial NCT04204616?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 500 participants. The study started on 2021-01-11. Estimated completion is 2026-10-26.
What conditions does trial NCT04204616 study?
This clinical trial studies the following conditions: Prurigo Nodularis.
What interventions are being tested in trial NCT04204616?
The interventions under investigation include: Nemolizumab (DRUG).
Who is sponsoring clinical trial NCT04204616?
This trial is sponsored by Galderma R&D, which has 158 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04204616 being conducted?
This trial has 20 study locations across Alabama, California, District of Columbia, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Prurigo Nodularis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN2)
RECRUITING · Phase 3
-
A Study to Investigate the Pharmacokinetics and Safety of Dupilumab in Participants ≥6 Months to <18 Years of Age With Prurigo Nodularis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy and Safety Study of Povorcitinib in Participants With Prurigo Nodularis (STOP-PN1)
RECRUITING · Phase 3
-
A Phase 3, Placebo-controlled, Double-blind Study Assessing Rocatinlimab in Prurigo Nodularis
ACTIVE NOT RECRUITING · Phase 3
-
A Study to Assess the Efficacy and Safety of Nemolizumab (CD14152) in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
-
A Study to Evaluate the Efficacy and Safety of Ruxolitinib Cream in Participants With Prurigo Nodularis (PN)
COMPLETED · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.